The Committee for Advanced Therapies (CAT) is a committee of the European Medicines Agency (EMA). The CAT is responsible for the scientific and technical assessment of advanced therapy medicinal products (ATMPs).
This includes gene therapy, somatic cell therapy, and tissue-engineered products.
The CAT also provides scientific advice to the European Commission, Member States, and other stakeholders on all aspects related to the development and use of ATMPs.
The CAT comprises 28 experts with backgrounds in basic research, clinical research, manufacturing, regulation, and ethicists. It also has nine alternate members. The Committee meets approximately every two months in a public session in Amsterdam.